Megumi Murakami

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (7)

• Vodobatinib overcomes cancer multidrug resistance by attenuating the drug efflux function of ABCB1 and ABCG2
  European Journal of Pharmacology 2025 DOI: 10.1016/j.ejphar.2024.177231
  +Save
• ABCG2 Mediates Resistance to the Dual EGFR and PI3K Inhibitor MTX-211 in Cancer Cells
  International Journal of Molecular Sciences 2024 DOI: 10.3390/ijms25105160
  +Save
• Imperatorin Restores Chemosensitivity of Multidrug-Resistant Cancer Cells by Antagonizing ABCG2-Mediated Drug Transport
  Pharmaceuticals 2023 DOI: 10.3390/ph16111595
  +Save
• Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells
  International Journal of Molecular Sciences 2023 DOI: 10.3390/ijms241813972
  +Save
• ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines
  Cells 2023 DOI: 10.3390/cells12071056
  +Save
• Design, Synthesis and Biological Evaluation of Quinazolinamine Derivatives as Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors with Improved Metabolic Stability
  Biomolecules 2023 DOI: 10.3390/biom13020253
  +Save
• Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein
  Proceedings of the National Academy of Sciences 2020 DOI: 10.1073/pnas.2016270117
  +Save